Table 2.
Relationship between periostin (POSTN) expression in the stromal cells (CAFs) and selected clinicopathological parameters in non-small cell lung cancer (NSCLC) patients and in two histological subtypes: adenocarcinoma (AC) and squamous cell cancer (SCC).
| Characteristics | NSCLC (N = 700) | AC (N = 330) | SCC (N = 370) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| POSTN Expression by CAFs | POSTN Expression by CAFs | POSTN Expression by CAFs | |||||||
| Low | High | Chi2 Test p-Value | Low | High | p-Value | Low | High | Chi2 Test p-Value | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
| Age | |||||||||
| ≤63 | 182 (26%) | 194 (27.7%) | 0.76 | 101 (30.6%) | 89 (27%) | 0.33 | 81 (21.9%) | 105 (28.4%) | 0.99 |
| >63 | 158 (22.6%) | 166 (23.7%) | 78 (23.6%) | 62 (18.8%) | 80 (21.6%) | 104 (28.1%) | |||
| Tumour size | |||||||||
| pT1 | 97 (13.9%) | 75 (10.7%) | 0.03 | 52 (15.8%) | 27 (8.2%) | 0.03 | 45 (12.2%) | 48 (13%) | 0.27 |
| pT2–pT4 | 243 (34.7%) | 285 (40.7%) | 127 (38.5%) | 124 (37.6%) | 116 (31.4%) | 161 (43.6%) | |||
| Grade | |||||||||
| G1 | 37 (5.3%) | 5 (0.7%) | <0.0001 | 31 (9.4%) | 1 (0.3%) | <0.0001 | 6 (1.6%) | 6 (1.6%) | 0.15 |
| G2 | 247 (35.3%) | 271 (38.7%) | 111 (33.6%) | 106 (32.1%) | 136 (36.8%) | 165 (44.6%) | |||
| G3 | 53 (7.6%) | 87 (12.4%) | 35 (10.6%) | 46 (13.9%) | 18 (4.9%) | 39 (10.5%) | |||
| Lymph node involvement | |||||||||
| pN0 | 238 (34%) | 211 (30.1%) | 0.005 | 126 (38.2%) | 83 (25.2%) | 0.02 | 112 (30.3%) | 128 (34.6%) | 0.1 |
| pN1, N2 | 102 (14.6%) | 149 (21.3%) | 53 (16.1%) | 68 (20.6%) | 49 (13.2%) | 81 (21.9%) | |||
| Stage | |||||||||
| I | 149 (21.3%) | 105 (15%) | 0.0001 | 83 (25.2%) | 40 (12.1%) | 0.0006 | 65 (17.6%) | 66 (17.8%) | 0.1 |
| II-IV | 191 (27.3%) | 255 (36.4%) | 96 (29.1%) | 111 (33.6%) | 95 (25.7%) | 144 (38.9%) | |||
Significant p-values are given in bold. NSCLC—non-small cell lung cancer; AC—adenocarcinoma; SCC—squamous cell carcinoma.